HSBC has upgraded Thermo Fisher Scientific Inc (TMO) from Hold to Buy as of November 30, 2025. The current share price stands at $588.32.
This upgrade reflects a more optimistic outlook on Thermo Fisher's prospects, suggesting improved fundamentals or enhanced confidence in the company’s strategic direction. The firm, headquartered in Waltham, Massachusetts, operates in the Life Sciences Tools & Services industry and employs approximately 125,000 individuals. It provides a diverse range of products and services that support the scientific community, including reagents, instruments, and diagnostic test kits.
As of November 27, 2025, Thermo Fisher has a market capitalisation of $222.9 billion, a P/E ratio of 33.95, and an EPS of 17.30. The company also offers a dividend yield of 29.0%. Upcoming earnings reports are scheduled for July 21, 2026, with estimated EPS of $5.94 and revenue of $11.6 billion, followed by April 21, 2026, with estimates of $5.64 EPS and $11.1 billion in revenue.
Analyst ratings serve as professional assessments based on rigorous research. As of December 1, 2025, the consensus among analysts is classified as Buy, with 8 Strong Buy, 17 Buy, and 6 Hold ratings. It is important to note that these ratings can evolve as new information emerges, reflecting varying opinions among analysts on the company’s performance and outlook.